

Technology Appraisal Committee A Interests Register

Topic: Dupilumab for treating moderate to severe chronic obstructive pulmonary disease [ID6235]

Publication Date: TBC.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Patrick de Barr	TAC A member	Direct - Financial Interests	Patrick currently receives paid employment by GSK who have approved products in COPD and i believe are a potential future comparator in this area.	07/07/2025 10/03/2025	It was agreed that Patrick's declaration would prevent him from participating in discussions on this appraisal.
Steve Edwards	TAC A member	Direct - Professional	Steve is a member of the EAG assessing ID6235	14/07/2025 11/03/2025	It was agreed that Steve's declaration would prevent him from participating in discussions on this appraisal.
Dominic Pivonka	TAC A Member	Direct - Financial Interests	Dominic's employer (AbbVie) markets a treatment in another disease area (atopic dermatitis) which is a competitor to dupilumab	15/07/2025 14/03/2025	It was agreed that Dominic's declaration would prevent him from participating in discussions on this appraisal.
Professor Richard Russel	Clinical Expert	Direct - Financial	Sanofi. £540. Speaker fee for the Spotlight COPD educational meeting, Southampton 11th June 2024. Not related to product, purely	05/08/2025	It was agreed that Professor Russel's declaration would not prevent him from providing

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>about COPD and its burden in Hampshire.</p> <p>Sanofi. Fee for attending Sanofi advisory meeting £960. Held virtually. 26 January 2024. Not related to the product. Advisory board to plan series of events on COPD and the burden of this disease – Spotlight COPD.</p>	05/08/2025	expert advice to the committee.
		Direct non-Financial	<p>Professor Russel is the chair of the British Thoracic Society (from Dec 2024).</p> <p>Professor Russel is the editor in chief of the International Journal of COPD</p> <p>Active Researcher in the field of COPD and have completed one trial of biologic therapy in COPD as a co-investigator (not for dupilumab).</p>		It was agreed that Professor Russel's declaration would not prevent him from providing expert advice to the committee.